Cargando…

Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues

Clinical features of idiosyncratic drug induced liver injury (DILI) are well described in cases that have been assessed for causality using the Roussel Uclaf Causality Assessment Method (RUCAM), but our understanding of the mechanistic steps leading to injury is fragmentary. The difficulties describ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teschke, Rolf, Uetrecht, Jack
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Article on Unresolved Basis Issues in Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106057/ https://www.ncbi.nlm.nih.gov/pubmed/33987428 http://dx.doi.org/10.21037/atm-2020-ubih-05

Ejemplares similares

Unresolved basic issues in hepatology
por: Weiskirchen, Ralf, et al.
Publicado: (2021)

The role of bile acids in cholestatic liver injury
por: Cai, Shi-Ying, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
por: Tacke, Frank, et al.
Publicado: (2021)

Mechanistic Studies of Idiosyncratic DILI: Clinical Implications
por: Uetrecht, Jack
Publicado: (2019)

Exosomes as therapeutic vehicles in liver diseases
por: Ding, Jingyi, et al.
Publicado: (2021)

Liver failure—future challenges and remaining questions
por: Lemmer, Peter, et al.
Publicado: (2021)

Non-alcoholic fatty liver diseases: current challenges and future directions
por: Roeb, Elke
Publicado: (2021)

It’s all about the spaces between cells: role of extracellular matrix in liver fibrosis
por: Khurana, Amit, et al.
Publicado: (2021)

Diagnostic management of nonalcoholic fatty liver disease: a transformational period in the development of diagnostic and predictive tools—a narrative review
por: Rosso, Natalia, et al.
Publicado: (2021)

Autoimmune hepatitis—is histology conclusive?
por: Beer, Andrea, et al.
Publicado: (2021)

Dairy consumption and hepatocellular carcinoma risk
por: Melnik, Bodo C.
Publicado: (2021)

Therapeutic strategies in Wilson disease: pathophysiology and mode of action
por: Stremmel, Wolfgang, et al.
Publicado: (2021)

Revisiting hemochromatosis: genetic vs. phenotypic manifestations
por: Anderson, Gregory J., et al.
Publicado: (2021)

The neglected biliary mucus and its phosphatidylcholine content: a putative player in pathogenesis of primary cholangitis—a narrative review article
por: Stremmel, Wolfgang, et al.
Publicado: (2021)

Idiosyncratic Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI): Diagnostic Algorithm Based on the Quantitative Roussel Uclaf Causality Assessment Method (RUCAM)
por: Teschke, Rolf, et al.
Publicado: (2021)

Echocardiography in acute rheumatic fever
por: Ramakrishnan, S
Publicado: (2009)

Immune mechanisms of idiosyncratic drug-induced liver injury
por: Mak, Alastair, et al.
Publicado: (2017)

Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019
por: Teschke, Rolf
Publicado: (2019)

Molecular Idiosyncratic Toxicology of Drugs in the Human Liver Compared with Animals: Basic Considerations
por: Teschke, Rolf
Publicado: (2023)

Idiosyncratic Drug-Induced Liver Injury: Mechanistic and Clinical Challenges
por: Jee, Alison, et al.
Publicado: (2021)

Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
por: Segovia-Zafra, Antonio, et al.
Publicado: (2021)

Microphysiological Models for Mechanistic-Based Prediction of Idiosyncratic DILI
por: Stern, Sydney, et al.
Publicado: (2023)

Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993–Mid 2020: A Comprehensive Analysis
por: Teschke, Rolf, et al.
Publicado: (2020)

Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use
por: Teschke, Rolf, et al.
Publicado: (2023)

Idiosyncratic Drug Induced Liver Injury, Cytochrome P450, Metabolic Risk Factors and Lipophilicity: Highlights and Controversies
por: Teschke, Rolf, et al.
Publicado: (2021)

Idiosyncratic Drug Reactions: A 35-Year Chemical Research in Toxicology Perspective
por: Uetrecht, Jack
Publicado: (2022)

Models of Drug Induced Liver Injury (DILI) – Current Issues and Future Perspectives
por: Kuna, Lucija, et al.
Publicado: (2018)

Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method
por: Teschke, Rolf, et al.
Publicado: (2022)

Testing Possible Risk Factors for Idiosyncratic Drug-Induced Liver Injury Using an Amodiaquine Mouse Model and Co-treatment with 1-Methyl-d-Tryptophan or Acetaminophen
por: Cho, Tiffany, et al.
Publicado: (2021)

Clinical management of patients with drug‐induced liver injury (DILI)
por: Björnsson, Einar S.
Publicado: (2021)

The Role of Myeloperoxidase in Clozapine-Induced Inflammation: A Mechanistic Update for Idiosyncratic Drug-Induced Agranulocytosis
por: Sernoskie, Samantha Christine, et al.
Publicado: (2023)

Genetic variations in drug-induced liver injury (DILI): resolving the puzzle
por: Stephens, Camilla, et al.
Publicado: (2012)

Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes
por: Quintás, Guillermo, et al.
Publicado: (2021)

The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment
por: Moreno-Torres, Marta, et al.
Publicado: (2022)

CD248/endosialin critically regulates hepatic stellate cell proliferation during chronic liver injury via a PDGF-regulated mechanism
por: Wilhelm, Annika, et al.
Publicado: (2016)

Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials
por: Hey-Hadavi, Juliana, et al.
Publicado: (2021)

Comment: Drug-Induced Liver Injury (DILI) With Micafungin: The Importance of Causality Assessment
por: Danjuma, Mohammed, et al.
Publicado: (2020)

Role of Hepatocyte Transporters in Drug-Induced Liver Injury (DILI)—In Vitro Testing
por: Tátrai, Péter, et al.
Publicado: (2022)

Mechanisms of liver disease in patients infected with HIV
por: Kaspar, Matthew B, et al.
Publicado: (2017)

Hyperbilirubinaemia in HIV–HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?
por: Kaspar, Matthew B, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gd404bijjplftjtsqgs7vnhgsj